Teva Pharmaceutical Industries Cash Flow Statement
NYSE: TEVAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Teva Pharmaceutical Industries free cash flow
In fiscal 2025, Teva Pharmaceutical Industries generated $1.65 billion of operating cash flow and spent $501.0 million on capital expenditures. That left free cash flow of $1.15 billion, a free-cash-flow margin of 6.7% of revenue. Free cash flow was up 53.3% from the prior year's $749.0 million.
Summary generated from market data by MetaCap's automated system. Methodology
Teva Pharmaceutical Industries cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 1.42B | -1.96B | -615.00M | -2.50B | 456.00M | -4.10B | -1.00B | -2.47B | -16.45B | 311.00M |
| Net Income growth (YoY) | — | — | — | -648.03% | — | — | — | — | -5389.07% | -75.18% |
| Depreciation & Amortization | 1.00B | 1.06B | 1.15B | 1.31B | 1.33B | 1.56B | 1.72B | 1.84B | 2.11B | 1.52B |
| Stock-Based Compensation | 157.00M | 123.00M | 121.00M | 124.00M | 119.00M | 129.00M | 119.00M | 155.00M | 133.00M | 124.00M |
| Change in Working Capital | -1.37B | -435.00M | -72.00M | 1.35B | -1.70B | -2.19B | -896.00M | -1.82B | -1.65B | -116.00M |
| Operating Cash Flow | 1.65B | 1.25B | 1.37B | 1.59B | 798.00M | 1.22B | 748.00M | 2.45B | 2.23B | 3.89B |
| Capital Expenditures | -501.00M | -498.00M | -526.00M | -548.00M | -562.00M | -578.00M | -525.00M | -651.00M | -874.00M | -901.00M |
| Investing Cash Flow | 737.00M | 792.00M | 968.00M | 656.00M | 1.52B | 863.00M | 1.35B | 1.87B | 3.45B | -34.41B |
| Dividends Paid | — | — | — | — | — | — | — | -12.00M | -901.00M | -1.30B |
| Share Repurchases | — | — | — | — | — | — | — | — | 0 | 0 |
| Debt Issued | 2.30B | 0 | 2.45B | 0 | 4.97B | 0 | 2.08B | 4.43B | 506.00M | 25.25B |
| Debt Repaid | -4.11B | -1.64B | -4.15B | -1.37B | -6.65B | -1.87B | -3.94B | -7.45B | -3.30B | -999.00M |
| Financing Cash Flow | -2.15B | -1.79B | -1.91B | -1.49B | -2.17B | -1.89B | -1.93B | -3.35B | -5.75B | 25.22B |
| Net Change in Cash | 256.00M | 74.00M | 393.00M | 636.00M | 21.00M | 202.00M | 193.00M | 819.00M | -25.00M | -5.96B |
| Free Cash Flow | 1.15B | 749.00M | 842.00M | 1.04B | 236.00M | 638.00M | 223.00M | 1.79B | 1.35B | 2.99B |
This table shows 10 annual periods of Teva Pharmaceutical Industries's cash flow statement, from FY 2025 back to FY 2016, across 14 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow TEVA's reporting calendar. What is a cash flow statement?